Navigation Links
MusclePharm Announces Preliminary Third Quarter 2011 Results
Date:10/10/2011

DENVER, Oct. 10, 2011 /PRNewswire/ -- MusclePharm Corporation, a Nevada corporation ("MusclePharm" or the "Company") (OTCBB: MSLP), an expanding U.S. nutritional supplement company, is pleased to announce MusclePharm's preliminary financial results for the third quarter ending September 30, 2011.

On a preliminary basis, the Company expects unaudited gross revenues for the three months ended September 30, 2011 of approximately $5,700,000, an increase of 305% as compared to gross revenues of $1,409,016 during the corresponding three month period ended September 30, 2010.   The company sales for the first nine months of 2011 are approximately $13,000,000, which is an increase of 325%, compared to all of 2010 sales of $4,000,000.

Commenting on the preliminary results, Brad Pyatt, Chief Executive Officer said, "We are extremely pleased with our enormous revenue growth we experienced during the third quarter of 2011.  Our expanding product line and distribution combined with our brand recognition positions us for accelerated growth over the coming months."

Mr. Pyatt continued, "The recent additions of COO John Bluher and President Jeremy Deleuca speak volumes on the long term direction of the company and what we are striving to build at MusclePharm. Both these two proven professionals are amazing assets to our company and will add tremendous stability and overall structure as we gear up for continued growth."

The Company expects to report a small net operating loss and a loss associated with convertible financing derivatives for the three months ended September 30, 2011.

ABOUT MUSCLEPHARM CORPORATION

Headquartered in Denver, Colorado, MusclePharm is a healthy life-style company that develops and manufactures a full line of NSF and Informed Choice approved nutritional supplements that are free of banned substances.  Based on years of research at the MusclePharm Sports Science Center, the products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than one hundred elite professional athletes from various professional sports leagues including the National Football League, Mixed Martial Arts, and Major League Baseball.  The Company's products address all categories of an active lifestyle, including muscle building, weight loss and maintaining general fitness through a daily nutritional supplement regimen.  MusclePharm is sold in over 120 countries and available in over 5,000 U.S. retail outlets, including GNC and Vitamin Shoppe, and Vitamin World.  MusclePharm products are also sold in over 100 online stores, including bodybuilding.com, Amazon.com and Vitacost.com.  For more information, please visit www.musclepharm.com.

FORWARD LOOKING STATEMENTS

The information contained herein includes forward-looking statements.  These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.  You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.  Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity.  We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Investor Contact:
Cory Gregory
President
303-396-6100
http://www.musclepharm.com


'/>"/>
SOURCE MusclePharm Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Former Pfizer Inc. Senior Director Joins Growing MusclePharm Medical Advisory Board
2. Cyberonics Announces Resignation of James A. Reinstein, Senior Vice President & Chief Commercial Officer
3. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
4. Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
5. Akorn, Inc. Announces Third Quarter 2011 Earnings Release and Conference Call Information
6. China Biologic Announces Changes in Directors
7. Facial Plastic Surgeon, Dr. Davis B. Nguyen Announces Fibrin Glue Approved by FDA for Use In Facelifts
8. Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function
9. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
10. Express Scripts Announces Revised 2011 Financial Guidance
11. Scios Inc. Announces Agreement with Department of Justice Regarding NATRECOR®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... , Tenn. and DALLAS , April ... EndoStim, Inc., announced that the first patients in ... the EndoStim device in the Lower Esophageal Sphincter Stimulation ... a minimally-invasive implantable device designed to provide long-term reflux ... neurostimulation. GERD affects nearly 65 million people ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... ... the adoption of e-prescribing as measured in Part D Medicare data. The dataset, ... to pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") ...
(Date:4/26/2017)... ... 2017 , ... Infertility may be a result of an ... many women become pregnant upon treating their diagnosis. , To properly ... We can provide the necessary information to diagnose and treat your problem. ...
(Date:4/26/2017)... ... 26, 2017 , ... New SUPRO® XT55 Isolated Soy ... by helping beverage manufacturers more effectively manage protein costs. “Soy protein has always ... well as more stable pricing over time. Now it’s even more relevant as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , ... . This new addition to the Mirroring360 product family combines device screen mirroring ... Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror app ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
Breaking Medicine News(10 mins):